Immuron us dod naval medical research center responds to fda clinical hold for new campylobacter etec therapeutic

Melbourne, australia, jan. 25, 2023 (globe newswire) -- immuron limited (asx: imc; nasdaq: imrn), an australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, today announces that a response letter has been submitted to the us food and drug administration (fda). immuron has previously reported feedback was received from the fda following a review of the investigational new drug (ind) application (asx announcement july 26, 2022) of a new oral therapeutic targeting campylobacter and etec developed in collaboration with immuron. the fda informed the nmrc that based on its review of the nonclinical data, the agency was placing a clinical hold on the clinical trials of the new oral therapeutic under the ind application.
IMRN Ratings Summary
IMRN Quant Ranking